TY - JOUR
T1 - Efficacy of mouth rinse in preventing oral mucositis in patients receiving high-dose cytarabine for allogeneic hematopoietic stem cell transplantation
AU - Mori, Takehiko
AU - Hasegawa, Kaori
AU - Okabe, Ai
AU - Tsujimura, Natsuki
AU - Kawata, Yusuke
AU - Yashima, Tomoko
AU - Kobayashi, Naoko
AU - Kondo, Sakiko
AU - Aisa, Yoshinobu
AU - Kato, Jun
AU - Tsunoda, Kazuyuki
AU - Nagai, Tetsuo
AU - Nakagawa, Taneaki
AU - Shigematsu, Naoyuki
AU - Kubo, Atsushi
AU - Ikeda, Yasuo
AU - Okamoto, Shinichiro
PY - 2009/12
Y1 - 2009/12
N2 - High-dose cytarabine is one of the major components of the conditioning regimen for hematopoietic stem cell transplantation (HSCT), and frequently causes severe oral mucositis. We have recently demonstrated that cytarabine is excreted into the saliva in patients receiving high-dose cytarabine, and proposed that it might locally and directly contribute to the development of oral mucositis. Therefore, this study was performed to assess whether removing the excreted cytarabine in the saliva by intensive mouth rinse during high-dose cytarabine infusion could reduce the incidence of oral mucositis. Fifteen patients with hematologic malignancies undergoing allogeneic HSCT who received total body irradiation (12 Gy) and high-dose cytarabine at a dose of 3 g/m 2 every 12 h for 4 days as a conditioning were evaluated. Patients were instructed to rinse their mouths using ice-cold water every 10 min, starting simultaneously with the 2-h cytarabine infusion and continuing up to 1 h after completion of each infusion. Oral mucositis was graded on a daily basis according to the National Cancer Institute, Common Toxicity Criteria. Thirty-five patients who previously underwent the same conditioning without mouth rinse served as controls. The incidence of Grades 2-3 and Grade 3 oral mucositis was significantly reduced in patients who performed mouth rinse as compared with the controls (40 vs. 80%, P = 0.009; 0 vs. 25. 7%, P = 0.02). In conclusion, mouth rinse during and shortly after high-dose cytarabine infusion could be an effective and inexpensive measure in reducing the incidence of moderate to severe oral mucositis caused by high-dose cytarabine. This finding strongly suggests the role of cytarabine excretion in the saliva in the development of cytarabine-associated oral mucositis.
AB - High-dose cytarabine is one of the major components of the conditioning regimen for hematopoietic stem cell transplantation (HSCT), and frequently causes severe oral mucositis. We have recently demonstrated that cytarabine is excreted into the saliva in patients receiving high-dose cytarabine, and proposed that it might locally and directly contribute to the development of oral mucositis. Therefore, this study was performed to assess whether removing the excreted cytarabine in the saliva by intensive mouth rinse during high-dose cytarabine infusion could reduce the incidence of oral mucositis. Fifteen patients with hematologic malignancies undergoing allogeneic HSCT who received total body irradiation (12 Gy) and high-dose cytarabine at a dose of 3 g/m 2 every 12 h for 4 days as a conditioning were evaluated. Patients were instructed to rinse their mouths using ice-cold water every 10 min, starting simultaneously with the 2-h cytarabine infusion and continuing up to 1 h after completion of each infusion. Oral mucositis was graded on a daily basis according to the National Cancer Institute, Common Toxicity Criteria. Thirty-five patients who previously underwent the same conditioning without mouth rinse served as controls. The incidence of Grades 2-3 and Grade 3 oral mucositis was significantly reduced in patients who performed mouth rinse as compared with the controls (40 vs. 80%, P = 0.009; 0 vs. 25. 7%, P = 0.02). In conclusion, mouth rinse during and shortly after high-dose cytarabine infusion could be an effective and inexpensive measure in reducing the incidence of moderate to severe oral mucositis caused by high-dose cytarabine. This finding strongly suggests the role of cytarabine excretion in the saliva in the development of cytarabine-associated oral mucositis.
KW - Hematopoietic stem cell transplantation
KW - High-dose cytarabine
KW - Mouth rinse
KW - Oral mucositis
UR - http://www.scopus.com/inward/record.url?scp=64249095350&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=64249095350&partnerID=8YFLogxK
U2 - 10.1007/s12185-008-0181-5
DO - 10.1007/s12185-008-0181-5
M3 - Article
C2 - 18972188
AN - SCOPUS:64249095350
SN - 0925-5710
VL - 88
SP - 583
EP - 587
JO - International journal of hematology
JF - International journal of hematology
IS - 5
ER -